Dependence at the prescribed dose: what holds for each drug
Xanax, Lexotanil, Stilnox, Lyrica — the most widely prescribed sedatives and hypnotics. This section gathers, drug by drug, what the regulators themselves have already acknowledged. Nothing here is opinion: every claim carries its source.
REGULATORBENZODIAZEPINES XANAX · LEXOTANIL FDA 2020 · CSM 1988
Benzodiazepines cause dependence at the dose you were prescribed
Alprazolam (Xanax), bromazepam (Lexotanil), diazepam, lorazepam: all carry the same FDA boxed warning since September 2020 — physical dependence develops within a few days to a few weeks of steady use, at the prescribed dose, without any misuse.
Physical dependence is not addiction and not a personal failure. It means the body has adapted — and that stopping needs a plan, not a snap decision: abrupt discontinuation after prolonged use can cause seizures.
The approved duration of use is short: the UK Committee on Safety of Medicines set it at 2–4 weeks in total, including the tapering period, as far back as 1988 — a recommendation since embedded in European product information. If you have been taking the same pill for months or years, that alone is a reason to discuss the treatment with your doctor — not a reason to panic, and never a reason to stop abruptly.
[7] FDA Drug Safety Communication, 23.09.2020 · [51] UK Committee on Safety of Medicines, Current Problems 21 (1988)
Zolpidem (Stilnox/Ambien) in Greece: approved for weeks, dispensed for years
The newer hypnotics — chiefly zolpidem (Stilnox/Ambien), which accounts for 89.7% of the class in Greece — were approved for short-term treatment of insomnia. The national prescription database shows a different picture: 1,229,842 prescriptions to 156,554 patients in three years, with a median of 8 prescriptions per patient.
The most critical finding concerns age: 73.1% of patients were 65 or older, with a median age of 77. In older people, however, this class is listed among potentially inappropriate medications under the Beers Criteria, because of the increased risk of falls and hip fractures. In other words: the drug concentrates in exactly the population the guidelines say should avoid it.
If this concerns someone in your family, the right question for the doctor is not "should they quit?" but "is there a tapering plan, and what is the non-drug alternative for sleep?" — for chronic insomnia, cognitive behavioural therapy (CBT-I) is recommended as first-line treatment, ahead of hypnotics.
[11] Siafis S et al. BMC Psychiatry 2023;23:370 · [18] AGS Beers Criteria®, 2023 update · ACP 2016 on CBT-I
Pregabalin (Lyrica): the "non-psychiatric drug" that joined the same list
Pregabalin (Lyrica) and gabapentin (Neurontin) are widely prescribed for neuropathic pain and anxiety — and most patients do not think of them as psychiatric drugs at all. In January 2026 the UK regulator (MHRA) placed them in the same decision as benzodiazepines and Z-drugs: packaging will now state explicitly that the medicine "may cause addiction, dependence and withdrawal reactions".
The practically important part of the decision: before treatment begins, a strategy for reducing and stopping must be agreed with the patient. The exit plan is part of the prescription — not a problem to be solved "someday".
[19] MHRA Drug Safety Update, 08.01.2026 · advice of the Commission on Human Medicines
REGULATORTHE EXIT PLAN PRACTICAL STEPS
If you have been on them for a while: a plan, not abrupt stopping
Nothing on this page says to stop your medication. It says the opposite: abruptly stopping benzodiazepines is dangerous, and the safe exit is gradual, at a pace set by your symptoms — always with communication, monitoring and guidance from your treating doctor.
Three questions worth asking at your next appointment: for how much longer is this treatment intended; what is the tapering plan and when does it start; and what non-drug alternative exists for the problem that started it. For how often withdrawal occurs and what the studies show, see Antidepressant withdrawal; for services specialising in deprescribing, the directory of independent organisations.
[19] MHRA 08.01.2026 · [18] NICE NG215 (2022)
SHARE
Sources for this section
[7]FDA Drug Safety Communication — Benzodiazepines, boxed warning for dependence and withdrawal, 23.09.2020.
[11]Siafis S, Fountoulakis KN, Fragkidis V, Papazisis G. Prescribing Z-drugs in Greece: an analysis of the national prescription database from 2018 to 2021. BMC Psychiatry 2023;23:370. doi:10.1186/s12888-023-04793-x
[18]NICE NG215 — Medicines associated with dependence or withdrawal symptoms (2022); NICE NG222 — Depression in adults (2022); Royal College of Psychiatrists, position statement on antidepressants (2020); AGS Beers Criteria®, 2023 update.
[19]MHRA Drug Safety Update — "Improving information supplied with gabapentinoids (pregabalin/gabapentin), benzodiazepines and z-drugs", 08.01.2026. gov.uk
[51]UK Committee on Safety of Medicines. Benzodiazepines, dependence and withdrawal symptoms. Current Problems 1988;21:1–2 — the 2–4-week maximum-duration recommendation, since embedded in NICE, MHRA and European product information.
Written byPetros Chatzianastasiou I am not a doctor. Every claim cites its primary source. Any step you take with your own treatment, always in consultation with your treating doctor and under their monitoring and guidance.